Novo Nordisk $NVO: Profits Surge Amid Rising Obesity Drug Demand,...
Key Takeaways Novo Nordisk has cemented its dominance in the burgeoning anti-obesity medication market, which is projected to exceed USD 82 billion by 2032, driven by its high-margin GLP-1 drugs,...